By Dr. Guillermo Zamora, a surgeon UAG, Homeopath (Dhom. Med) by the Institute for Homoeopathic Medicine.

For those who question the strength of the inductive method of reasoning applied to medicine proposed by Hahnemann, put as an example if not its antithesis, if it is unduly partial observation of an event, the report that for several days been going on for the journal Public Library of Science Pathogens [1] and has been published in various journals, conferences, websites, and magazines [2].
This report mentions that a genetically modified virus [“oncolytic” herpes simplex virus (HSV)] has been created, and is able to block the spread of ovarian cancer and breast cancer in mice. It seems important to mention that different sources of conventional medicine, have been saying this for several years.
Chief Scientist, Professor Gabriella Campadelli-Fiume, University of Bologna in Italy, said: “Many laboratories worldwide are using more specific viruses as weapons against cancer cells, called oncolytic viruses.”
“Safety concerns prevailed so far, and all oncolytic herpes virus now in clinical trials are weakened viruses, effective only against a fraction of tumors.”
“We were the first to obtain a reprogrammed herpes virus to enter positive tumor cells, unable to infect other cells, but retains the same ability to kill in order that the wild-type HSV.”
According to Dr. Kevin Harrington, Institute of Cancer Research in London, who is leading oncolytic virotherapy studies [3], has been obtained “success” in up to 93% of cases in which the virus (and other viruses such as reovirus and adenovirus) has been modified to not infect healthy tissue (?) and according to the studies could become successful treatment in the fight against head and neck cancer.
With FDA approval, studies (including multicenter) are carried out in different phases using intratumoral injection in order to evaluate the response of colony stimulating factor-granulocyte macrophage [JS1/34.5-/47-/granulocyte -macrophage colony-stimulating factor (GM-CSF)] in different types of advanced cancer. Studies may include combinations of chemotherapy with cyclophosphamide, docetaxel, 3-AP Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone), radiation therapy, or combined chemoradiation in which studies show is “synergy” between all therapies. Side effects such as anemia, nausea, and fatigue are often reported, and neutropenia. One speaks of proviral states as vascular endothelial growth factor (vascular endothelial growth factor or VEGF) during which the reovirus can replicate oncolytic administered systemically in the endothelium, thereby inducing immune-mediated vascular collapse with significant antitumor properties.
Many studies show how are you amazing results with proven results in the treatment of certain cancers. However, the long term effects of drug-biological treatments, dependence and the tendency to acquire another disease state or immune weakness, are some maxims that should worry us. No medical intervention or treatment should be given without a long period of experimentation and testing (*). A Hahnemann It took eight years before he started dealing with Homoeopathy. There are many books, documents and writings and research experiments on the reactions, similarities, and results before he carefully follow each step with your therapy.
(*) This warning applies also for studies with the name “Homoeopathy” is conducted for cancer treatment (for example the protocol Banerji Homeopathic Research Foundation), especially when real has not been practiced homeopathy for decades for most of the “homeopathic”.
Something that has not been taken into account is that one thing is the infectious agent with whom you work for any purpose, and one is the reaction-disease so mild, moderate or severe body generates all contacts that agent. Any modified agent however, can not be discriminative enough not to cause a reaction in the center of the life force (wherever it is), as we saw with the immediate side effects reported as anemia, nausea, fatigue and neutropenia.
The experimental study is developed with the herpes virus, derived from observation (as I said at the beginning, unduly partial) that people with cancer and at the same time acquire or come into contact with people infected with the herpes virus appear stop development of its initial cancerous state, and even reverse it [4]. (I translate an extract of the reference number 4 on the history of oncolytic therapy, for the convenience of our readers)
“It seems that the use of viruses in cancer treatment was not the result of some insightful theory of alternative therapy, but rather only derived from the observation that, occasionally, cancer patients who contracted an infectious disease had brief periods clinical remission. “
So, we put a lot of attention. We must not lose the entire complex under which certain conditions are favoring the experimental subjects, who were either inmunosuprime (even when it is intended to search a localized immune response), or causes them to weaken their disease through chemo and / or radiation while trying to “attack” the tumor with the modified virus. This means that protocols require that artificially weaken, suppress or maintain and produce a susceptibility to opportunistic infectious miasm widely known, but enough to make it amended as yet unknown. With this, it will be predicted drug dependence or ultimately death because desarmonizado balance that sustains life. We will see later why.
This herpes and cancer research leads me to remember what Hahnemann had observed about through simple inductance and I would have liked to have been taken into account by the researchers (or perhaps if they knew about it?). This would comment that we do not object to people using their preferred therapy or oppose personal opinions. What we would like is that these observations are considered under Baconian establish a new era in science as applied to medicine.
I can not leave out, mention the fact that prior experimentation on animals has serious drawbacks, including:
- Animals can not express subjective symptoms produced during the experiment.
- Infective agents (read infecting agent perspective Hahnemanniana) act differently in each species.
- Humans and animals react differently to these infectious agents.
- There are substances in animals may be harmless, while for men can be highly toxic and vice versa.
- Man or animal (host) can act as a reservoir and in turn so individualized in each body of each species cause changes (mutations) to infective agents making them more potent complexes, reactivándolos (eg after attenuated) or increasing their virulence ( **).
(**) Vaccines may also be applied to the same vial containing three viruses or vaccines contaminated with unknown viruses. [5, 6.7 to cite some references, but there is enough hemerography about]
As I mentioned before and want to accept it or not researchers oncolytic viral therapy (they did not know, did not understand, did not care or did purposely. No) [4], for almost 200 years, Hahnemann had already observed in As regards to the reaction-disease, three circumstances where two dissimilar diseases coexist in the body of a human being, I quote two of those three circumstances with some of his remarks and references:
Aphorism § 38, Organon, 6th. edition
“II. – New to dissimilar disease is the strongest. – In this case the disease under which the patient lived primitively, being the weakest, will be arrested and suspended by the emergence of stronger, until it cross its course or be cured, then the old reappears uncured. ‘
- “As noted Tulpius 72 two children suffering from some form of epilepsy, were free of attacks after being infested with ringworm (instep), but as soon as the eruption of epilepsy head disappeared again as before. (72 Obs., lib. i, obs. 8)
- Scabies, as noted Schopf 73 submitted scurvy disappeared, but after it healed, that reappeared. (72 Obs., lib. i, obs. 8)
- So also remained stationary pulmonary tuberculosis patient being attacked by a violent typhus, but continued their march after typhus ran its course. 74 (74 Chevalier, in Hufeland’s Neuesten Annalen der Französiche, Heiljunde, ii, p. 192)
- When the measles and smallpox together dominate, and both attack the same child, measles-existing, generally is contained by smallpox appeared later; measles does not end until it ends its course smallpox, but not uncommon it happens that the smallpox infection is suspended for four days by the supervening of measles, after which scaling complete your smallpox, as observed by Manget. 76 (76 In Edimb. Med Comment., Pt. I, I)
- So with all dissimilar diseases, the strongest stops development of the weakest (if not complicated which is rare in acute diseases), but never a cure to the other. “(My emphasis)
The aphorism § 40, 6th Organon. Editing refers to a combined response (or response miasmatic disease combined mutant)
“III. – The new disease, after he had worked a long time in the body, finally joins that is unlike the former, and forms with it a complex disease, so that each occupies a special location in the body, ie organs peculiarly adapted to it and only that particular location belongs, while leaving the remaining organs other disease that is unlike … For two dissimilar diseases can not be destroyed, can not be cured to one another … not However, there have also been major epidemics of this kind, in which two dissimilar acute and, in rare cases, have occurred simultaneously in one and the same body, and combined, as it were, for a short time with each other … then, though not completely incurable, but can be transformed into health with very great difficulty. “
- “Rainey 86 witnessed the simultaneous occurrence of measles and smallpox in two girls. (86 Edinb. Med Comment, iii, p. 480)
- J. Maurice 87 throughout its practice observed only two cases of this kind. (87 in Phys Med and Journ., 1,805)
- Similar cases are found in the works of Ettmüller 88 and in the writings of some others. (88 Opera, ii, pi, chap. 10)
- Lencker 89 vaccine was go full term together with measles and purple. (89 Hufeland’s Journal, X v ii) “
This latter circumstance applies for malnourished patients, and / or with certain addictions, and / or debilitating conditions, and / or in immunosuppressed patients, etc. A clear example of this would be all diseases “new” appearance as acquired immunodeficiency syndrome (AIDS), in which you can combine various diseases caused by two or more types of the herpes family (***) and microorganisms and other viral, bacterial, fungal, etc..
(***) In the last 100 years have discovered 8 different types of herpes.
1.-TYPE herpes simplex virus I.
2.-Herpes Simplex Virus Type II
3.-varicella-zoster virus.
4.-Epstein-Barr virus.
5.-CITAMEGALOVIRUS.
6.-herpesvirus-6-6-B AY. (HHV-6)
7.-herpesvirus 7 (HHV-7)
8.-human herpesvirus 8 (Kaposi’s sarcoma)
If we reflect the foregoing, we find that Hahnemann makes complete observations (and NO partial), deep and detailed the circumstances between two dissimilar diseases coexist, including the aftermath of the same, so we can see that the inductance in science, observe the experienced (even from the same accident or toxicity), helps predict the outcome of an event. Take into account the principles established by Hahnemann in the Organon for experimentation and the coexistence of two dissimilar diseases is not a minor thing. Accept and understand our limitations, our achievements, and the consequences of such applications in medicine is vital to our future and wellbeing.
References
[1] http://www.plospathogens.org/
[2] Huffingtonpost, Herpes Virus Could Be Key To Breast And Ovarian Cancer Treatment, The Huffington Post UK | Posted: 31/01/2013 22:16 GMT
GM virus blocks spread of cancer, Press Association – Thu, Jan 31, 2013, yahoo news.
Herpes virus, “new weapon” against cancer Join BBC Science, August 2, 2010 – 13:39 GMT
The herpes virus shows promise in treating breast cancer, Isaude, Science and Technology, published on 26/10/2011 at 13h58: 00
HERPES VIRUS SHOWS PROMISE IN TREATING EARLY TRIPLE-NEGATIVE BREAST CANCER Oncolytic viral therapy shows great potential for treating an aggressive form of breast cancer, News from the Clinical Congress, Yuman Fong, MD, FACS Sepideh Gholami, MD, Monday, October 24, 1:00 pm
[3] Donnelly, OG., Errington-Mais, F., Prestwich, R., Harrington, K., Pandha, H., Vile, R. & Melcher, AA. (2012) Recent Clinical Experience with oncolytic Viruses Current Pharmaceutical Biotechnology, Vol.13 (9), pp.1834-1841, ISSN: 1389-2010.
Adair, RA., Roulstone, V., Scott, KJ., Morgan, R., Nuovo, GJ., Fuller, M., Beirne, D., West, EJ., Jennings, VA., Rose, A., et al. (2012) Cell Carriage, Delivery, and Selective Replication of an oncolytic virus in Tumor in Patients Science Translational Medicine, Vol.4 (138), ISSN: 1946-6234.
Karapanagiotou, MS., Roulstone, V., Twigger, K., Ball, M., Tanay, M., Nutting, C., Newbold, K., Gore, ME., Larkin, J., Syrigos, KN., et al. (2012) Phase I / II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with Advanced Malignancies. Clin Cancer Res, Vol.18 (7), pp.2080-2089, ISSN: 1078-0432 .
Simpson, GR., Horvath, A., Annels, NE., Pencavel, T., Metcalf, S., Seth, R., Peschard, P., Price, T., Coffin, RS., Mostafid, H., et al. (2012) Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for bladder cancer Surface British Journal of Cancer, Vol.106 (3), pp.496-507, ISSN: 0007-0920 .
Kottke, T., Chester, J., Ilett, E., Thompson, J., Diaz, R., Coffey, M. Selby, P., Nuovo, G., Pulido, J., Mukhopadhyay, D., et al. (2011) Precise Scheduling of Chemotherapy Primes VEGF-producing Tumors for Successful Systemic oncolytic virotherapy MOL THER, Vol.19 (10), pp.1802-1812, ISSN: 1525-0016.
Heinemann, L., Simpson, GR., Boxall, A., Kottke, T., Relph, KL., Vile, R., Melcher, A., Prestwich, R., Harrington, KJ., Morgan, R., et al. (2011) Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer BMC CANCER, Vol.11 ISSN: 1471-2407.
Touchefeu, Y., Vassaux, G. & Harrington, KJ. (2011) oncolytic viruses in radiation oncology Radiother Oncol, vol.99 (3), pp.262-270, ISSN: 0167-8140.
Ilett, EJ., Barcena, M., Errington-Mais, F., Griffin, S., Harrington, KJ., Pandha, HS., Coffey, M., Selby, PJ., Limpens, RWAL., Mommaas, M . et al. (2011) Internalization of oncolytic Reovirus by Human Dendritic Cell Carriers from the Virus Neutralization Protects Clin Cancer Res, Vol.17 (9), pp.2767-2776, ISSN: 1078-0432.
Willmon, C., Diaz, RM., Wongthida, P., Galivo, F., Kottke, T., Thompson, J., Albelda, S., Harrington, K., Melcher, A. & Vile, R. (2011) Vesicular Stomatitis Virus-induced Suppressor Cells Immune Antagonism Between Intratumoral oncolytic Generate Virus and Cyclophosphamide Mol Ther, Vol.19 (1), pp.140-149, ISSN: 1525-0016.
Senzer, NN., Kaufman, HL., Amatruda, T., Nemunaitis, M., Reid, T., Daniels, G., Gonzalez, R., Glaspy, J., Whitman, E., Harrington, K., et al. (2009) Phase II Clinical Trial of a Granulocyte-macrophage colony-stimulating factor-Encoding, Second-Generation oncolytic herpesvirus in unresectable Patients With Metastatic Melanoma J CLIN ONCOL, Vol.27 (34), pp.5763-5771, ISSN: 0732-183x.
Harrington, KJ. (2010) Topical treatment for oral Cancers Winners and Losers and oncolytic adenoviruses: who should be down in the mouth? GENE THER, Vol.17 (12), pp.1421-1422, ISSN: 0969-7128.
Harrington, KJ., Hingorani, M., Tanay, MA., Hickey, J., Bhide, SA., Clarke, PM., Renouf, LC., Thway, K., Sibtain, A., McNeish, IA., et al. (2010) Phase I / II Study of oncolytic HSVGM-CSF in Combination with Cisplatin in Untreated Radiotherapy and Stage III / IV Squamous Cell Cancer of the Head and Neck Clin Cancer Res, Vol.16 (15), pp.4005 -4015, ISSN: 1078-0432.
Merron, A., Baril, P., Martin-Duque, P., de la Vieja, A., Tran, L., Briat, A., Harrington, KJ., McNeish, IA. & Vassaux, G. (2010 ) Assessment of the Na / I symporter gene as a reporter to visualize oncolytic adenovirus propagation in peritoneal Tumours Eur J Nucl Med MOL I, Vol.37 (7), pp.1377-1385, ISSN: 1619-7070.
Kottke, T., Hall, G., Pulido, J., Diaz, RM., Thompson, J., Chong, H., Selby, P., Coffey, M., Pandha, H., Chester, J., et al. (2010) Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of tumors in mice Established J CLIN INVEST, Vol.120 (5), pp.1551-1560, ISSN: 0021-9738.
Harrington, KJ., Vile, RG., Melcher, A., Chester, J. & Pandha, HS. (2010) Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics. Cytokine Growth Factor Rev, Vol.21 (2-3), pp.91-98.
Senzer, NN., Kaufman, HL., Amatruda, T., Nemunaitis, M., Reid, T., Daniels, G., Gonzalez, R., Glaspy, J., Whitman, E., Harrington, K., et al. (2009) Phase II Clinical Trial of a Granulocyte-macrophage colony-stimulating factor-Encoding, Second-Generation oncolytic herpesvirus in unresectable Patients With Metastatic Melanoma J CLIN ONCOL, Vol.27 (34), pp.5763-5771, ISSN: 0732-183x.
Willmon, C., Harrington, K. Kottke, T., Prestwich, R. Melcher, A. & Vile, R. (2009) Cell Carriers for oncolytic Viruses: Fed Ex for Cancer Therapy MOL THER, Vol.17 (10), pp.1667-1676, ISSN: 1525-0016.
Prestwich, RJ., Errington, F., Steele, LP., Ilett, EJ., Morgan, RSM., Harrington, KJ., Pandha, HS., Selby, PJ., Vile, RG. & Melcher, AA. (2009) Reciprocal Human Dendritic Cell-Induced Natural Killer Cell Interactions Following Antitumor Activity Tumor Cell Reovirus Infection by oncolytic J Immunol, Vol.183 (7), pp.4312-4321, ISSN: 0022-1767.
Pandha, HS., Heinemann, L., Simpson, GR., Melcher, A., Prestwich, R., Errington, F., Coffey, M., Harrington, KJ. & Morgan, R. (2009) Synergistic Effects of oncolytic Reovirus and Cisplatin Chemotherapy in Murine Malignant Melanoma CLIN CANCER RES, Vol.15 (19), pp.6158-6166, ISSN: 1078-0432.
Prestwich, RJ., Errington, F., Diaz, RM., Pandha, HS., Harrington, KJ., Melcher, AA. & Vile, RG. (2009) The Case of oncolytic Viruses Versus the Immune System: Waiting on the Judgment of Solomon HUM GENE THER, Vol.20 (10), pp.1119-1132, ISSN: 1043-0342.
Prestwich, RJ., Ilett, EJ., Errington, F., Diaz, RM., Steele, LP., Kottke, T., Thompson, J., Galivo, F., Harrington, KJ., Pandha, HS., et al. (2009) Immune-Mediated Antitumor Activity of Reovirus Is Required for Therapy and Is Independent of Direct Viral Replication Oncolysis and CLIN CANCER RES, Vol.15 (13), pp.4374-4381, ISSN: 1078-0432.
Pandha, H., Melcher, A., Harrington, K. & Vile, R. (2009) oncolytic Viruses: Time to Compare, Contrast, and Combine? MOL THER, Vol.17 (6), pp.934-935, ISSN: 1525-0016.
Ilett, EJ., Prestwich, RJ., Kottke, T., Errington, F., Thompson, JM., Harrington, KJ., Pandha, HS., Coffey, M., Selby, PJ., Vile, RG., et al. (2009) Dendritic cells and T cells deliver Tumour killing oncolytic DESPITE reovirus for pre-existing anti-viral immunity Gene Ther, Vol.16 (5), pp.689-699, ISSN: 0969-7128.
Kottke, T., Thompson, J., Diaz, RM., Pulido, J., Willmon, C., Coffey, M., Selby, P., Melcher, A., Harrington, K. & Vile, RG. (2009) Improved Systemic Delivery of Established Tumors to Reovirus oncolytic Using Preconditioning with Cyclophosphamide-Mediated Treg Modulation and Interleukin-2 Clin Cancer Res, Vol.15 (2), pp.561-569, ISSN: 1078 – 0432.
Prestwich, RJ., Errington, F., Ilett, EJ., Morgan, RSM., Scott, KJ., Kottke, T., Thompson, J., Morrison, EE., Harrington, KJ., Pandha, HS., et al. (2008) Tumor Infection by oncolytic Reovirus Primes Adaptive Antitumor Immunity CLIN CANCER RES, Vol.14 (22), pp.7358-7366, ISSN: 1078-0432.
Prestwich, RJ., Harrington, KJ., Pandha, HS., Vile, RG., Melcher, AA. & Errington, F. (2008) oncolytic viruses: a novel form of immunotherapy EXPERT ANTICANC REV, Vol.8 (10), pp.1581-1588, ISSN: 1473-7140.
Harrington, KJ., Melcher, A., Vassaux, G., Pandha, HS. & Vile, RG. (2008) Exploiting Synergies Between radiation and oncolytic viruses. Curr Opin Mol Ther, Vol.10 (4), pp.362-370, ISSN: 1464-8431.
Prestwich, RJ., Harrington, KJ., Vile, RG. & Melcher, AA. (2008) immunotherapeutic potential of oncolytic virotherapy LANCET ONCOL, Vol.9 (7), pp.610-612, ISSN: 1470-2045.
Kottke, T., Galivo, F., Wongthida, P., Diaz, RM., Thompson, J., Jevremovic, D., Barber, GN., Hall, G., Chester, J., Selby, P., et al. (2008) Treg depletion-enhanced IL-2 therapy of treatment Facilitates Established tumors delivered systemically using oncolytic virus Mol Ther, Vol.16 (7), pp.1217-1226, ISSN: 1525-0016.
White, CL., Twigger, KR., Vidal, L., De Bono, JS., Coffey, M., Heinemann, L., Morgan, R., Merrick, A., Errington, F., Vile, RG. , et al. (2008) Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene Ther, Vol.15 (12), pp.911-920.
Qiao, J., Kottke, T., Willmon, C., Galivo, F., Wongthida, P., Diaz, RM., Thompson, J., Ryno, P., Barber, GN., Chester, J., et al. (2008) Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, immunotherapy and virotherapy oncolytic Nat Med, Vol.14 (1), pp.37-44, ISSN: 1078-8956.
Hu, JC., Coffin, RS., Davis, CJ., Graham, NJ., Groves, N., Guest, PJ., Harrington, KJ., James, ND., Love, CA., McNeish, I., et al. (2006) A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res, Vol.12 (22), pp.6737-6747, ISSN: 1078-0432.
[4] NATURE, Molecular Therapy (2007) 15 4, 651-659 doi: 10.10, “History of oncolytic Viruses: Genesis to Genetic Engineering”, Elizabeth Kelly and Stephen J Russell:
“It Appears That the use of viruses in the treatment of cancer was not the result of some perspicacious theory of an alternative therapy but Rather stemmed from the observation just That, occasionally, Contracted cancer patients who went into an infectious disease brief periods of clinical remission . “
[5] Modulation of immune responses during canine distemper virus infection: implications for therapeutic and vaccine development, Céspedes PF *, P Cruz, CO Navarro, Faculty of Veterinary and Animal Sciences, Laboratory of Animal Virology, University of Chile , Santiago, Chile. Arch Med Vet 42, 15-28 (2010):
“This last statement is based on evidence of the ability of the attenuated vaccine virus to revert to virulence so fleeting and cause lethal encephalitis in dogs following immunization and, similarly, a multisystem box of 90-100% morbidity and lethality in ferrets blacklegged (Mustela putorius furo) (Summers and Appel 1994, von Messling et al 2003). “
[6] Reverse Genetics for Live Attenuated Virus Vaccine Development Kun Yao, * and Zaishi Wang
“… An attenuated virus can still replicate in the Vaccinated Individuals, Therefore, the virus has the potential to revert to virulent phenotypes. Moreover, some of live vaccines can be Transmitted from the person to non immunized Vaccinated Individuals … “
“These are particularly important safety Concerns for Certain human RNA human parainfluenza viruses Such as virus (PIV), respiratory syncytial virus (RSV) and HIV, since viruses These RNA, RNA-dependent RNA Whose polymerases do not have a proofreading function and a high Could Occur During mutation rate virus replication. “
[7] Altered Virulence of Vaccine Strains of Measles Virus after Prolonged Replication in Human Tissue, Alexandra Valsamakis et al, J Virol. October 1999, 73 (10): 8791-8797.
THE U.S. MEDICAL SYSTEM IS THE NATION’S NUMBER ONE KILLER
By Rob Pell
March 11, 2013
NewsWithViews.com
Ideas for reducing unnecessary, preventable deaths in this country have been in the news a lot lately. Where shall we begin? Annual gun related homicides total about 11,000 and automobile fatalities are about 35,000 per year.
Would you be surprised to learn that the leading cause of death in the US
appears to be the medical system itself. This is the startling conclusion reached in a report published by medical researchers: Gary Null, PhD; Carolyn Dean MD, ND; Martin Feldman, MD; Debora Rasio, MD; and Dorothy Smith, PhD.
Deaths resulting from inadvertent, adverse effects or complications from medical treatment or diagnostic proceedures are known as Iatrogenisis, meaning: Brought forth by a healer (from the Greek iatros, healer).Their report places the number of annnual iatrgenic (brought forth by a healer) deaths in the US at 783,936.
Hippocrates is often regarded as the father of western medicine and 98% of American medical students swear to some form of the Hippocratic Oath before practicing medicine. One of the underlying principals of the Oath is: “first, do no harm.” I’m not sure if that’s sad or ironic.
The largest single contributor to iatrogenic deaths are prescription drugs, being used as directed. According to a report issued by Medical News Today, over 4 billion prescriptions were written for drugs in America in 2011 . That’s an average of over 13 for each man, woman and child. The average number of prescriptions written annually for a senior citizen is 28 per year. That doesn’t include over- the-counter medications or vaccines. If these drugs could successfully treat and cure disease, the United States would have the healthiest inhabitants on the planet.
The possible adverse reaction warnings on TV drug commercials have become a punch line for comedian’s routines, but, life-threatening side-effects are no laughing matter. Common side-effects of individual drugs are well publicized but it’s impossible for physicians or pharmacists to reliably predict what possible side-effects will occur when combining three, four, 13 or 28 different drugs.
I was recently saddened to read the obituary of one of my customers, a strongly-built Military Veteran in his mid-seventies, who appeared to me to be in excellent health five years ago. His son told me that he had reviewed his Dad’s prescriptions with him and was shocked to discover that 9 of the 12 drugs his father was taking had been prescribed to treat side-effects from one of the other drugs. His father was found dead, lying on the floor of his residence. No autopsy was performed.
The Journal of the American Medical Association (JAMA) published a study by Dr. Barbara Starfield, an MD with a Master’s degree in Public Health, revealing the extremely poor performance of the United States health care system in a number of areas.
One of Starfield’s main concerns is the lack of systematic recording and studying of adverse events stemming from prescription drugs. If a patient dies, there is no routine procedure to notify their physician, even if the patient is autopsied. Therefore, there is almost no way for the average doctor to link a patient’s death to a possible adverse reaction to a prescribed medication.
This is especially troubling because another article published in JAMA concluded prescription drugs, being used as directed, cause about 106,000 deaths a year and over two million serious injuries annually in the U.S. This makes prescription drugs the single largest factor in deaths induced by the medical establishment.
Nationally, only about 20% of all deaths are subject to investigation by a coronor or medical examiner. If the cause of death was made certain in all cases by autopsy, I’m quite sure that the number of deaths actually caused by prescription drugs, being used as directed, would dwarf the 106,000 per year the JAMA report acknowleged.
I’ve seen enough to believe that in many cases Big-Pharma is far more concerned with creating repeat, lifetime customers rather than finding cures. Joining the drug companies, the FDA and insurance companies are the kingpins behind this profit-driven business model. Some call doctors well-meaning, unsuspecting pawns of Big-Pharma. Others call them street level pushers for FDA sanctioned drug cartels. Either way, the kingpins couldn’t do it without medical doctors helping them complete the drug delivery system.
Due to concerns about dangerous side-effects from long-term use, many prescription drugs were, at one time, specifically prescribed only for short-term use Now, just a few years later, many of the same drugs are routinely prescribed, indefinitely, for the rest of your life.
Further, the Null-Dean report showed that the number of people exposed to unnecessary hospitalization annually is 8.9 million per year. This is cause for concern because a 2008 study issued by the Office of Inspector General for the Department of Health and Human Services, reported that one in seven Medicare beneficiaries who is hospitalized will be harmed as a result of the medical care they receive in the hospital.
Prescription drugs and hospital visits are very risky business. Unlike with other more well publicized causes of death, simply taking greater personal responsibility for our own health and well-being could save hundreds of thousands of lives every year. Unfortunately, more gun or traffic laws will do nothing to save us from what is actually the Nation’s number one killer, the U.S.medical system.
2 Comments
Posted in Admin Comment, News, Public
Tagged Allopathic medical problems, Disease, Medicine poisoning